Some experience of the use of etomidate in children

Area of Science:

• Anesthesiology
• Pediatric Medicine
• Pharmacology

Background:

• Etomidate is an intravenous hypnotic agent used for anesthesia induction.
• Its safety and efficacy in pediatric populations require thorough evaluation.
• Cardiovascular and respiratory stability are critical during anesthetic induction.

Purpose of the Study:

• To evaluate the safety and efficacy of etomidate as an intravenous hypnotic for anesthesia induction in children.
• To assess the incidence of side-effects, specifically pain and myoclonus.
• To determine the adequacy of the 0.2 mg/kg dose in unpremedicated pediatric patients.

Main Methods:

• A study involving 198 children undergoing anesthesia induction.
• Administration of etomidate at a dose of 0.2 mg/kg intravenously.
• Monitoring for cardiovascular and respiratory effects.
• Assessment of post-injection pain and myoclonic activity.

Main Results:

• Etomidate demonstrated no appreciable side-effects on the cardiovascular or respiratory systems.
• A high incidence of post-injection pain (27%) was observed.
• A significant incidence of myoclonia (10%) occurred.
• The 0.2 mg/kg dose was found to be inadequate for anesthesia induction in unpremedicated children.

Conclusions:

• Etomidate can be considered a safe agent regarding cardiovascular and respiratory stability in pediatric anesthesia induction.
• The high rates of pain and myoclonus necessitate further investigation or alternative strategies.
• The current dose of 0.2 mg/kg is insufficient for effective anesthesia induction in unpremedicated children, suggesting a need for dose adjustment or premedication.